The pharmaceutical holding “Nacimbio,” part of the Rostec State Corporation, has completed the delivery of vaccines for the planned immunization of the population in 2024, providing a total of 108 million doses to various regions in Russia. These vaccines protect against diseases such as measles, rubella, mumps, tetanus, diphtheria, whooping cough, tuberculosis, hepatitis B, and influenza.
According to the organization’s press service, all Russian regions have received the vaccines for preventing viral and bacterial infections. The deliveries were made strictly according to the timelines set out in government contracts, with shipments of the flu vaccine arriving a month ahead of schedule.
“All supplied products are manufactured in Russia through a full-cycle process, including the crucial stage of active ingredient production. This approach eliminates our dependency on foreign manufacturers for the National Calendar of Preventive Vaccinations,” said Andrey Zagorsky, CEO of Nacimbio.
